Total Payments
$222,168
2024 Payments
$27,213
Companies
34
Transactions
235
Medicare Patients
725
Medicare Billing
$109,260
Payment Breakdown by Category
Consulting$174,742 (78.7%)
Other$25,951 (11.7%)
Research$8,985 (4.0%)
Travel$7,605 (3.4%)
Food & Beverage$4,021 (1.8%)
Education$863.20 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $174,742 | 80 | 78.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,701 | 9 | 6.6% |
| Honoraria | $11,250 | 6 | 5.1% |
| Unspecified | $8,985 | 15 | 4.0% |
| Travel and Lodging | $7,605 | 52 | 3.4% |
| Food and Beverage | $4,021 | 70 | 1.8% |
| Education | $863.20 | 3 | 0.4% |
Payments by Type
General
$213,182
220 transactions
Research
$8,985
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $36,616 | 61 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $30,813 | 28 | $0 (2024) |
| Incyte Corporation | $24,927 | 23 | $0 (2023) |
| BioNTech SE | $16,783 | 7 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $11,400 | 2 | $0 (2024) |
| Merck Sharp & Dohme LLC | $9,579 | 11 | $0 (2022) |
| Innate Pharma, Inc | $7,920 | 1 | $0 (2021) |
| Genentech, Inc. | $7,754 | 8 | $0 (2020) |
| AbbVie, Inc. | $7,558 | 6 | $0 (2019) |
| Seattle Genetics, Inc. | $6,612 | 14 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $27,213 | 13 | Teva Pharmaceuticals USA, Inc. ($11,400) |
| 2023 | $21,571 | 22 | Regeneron Pharmaceuticals, Inc. ($6,046) |
| 2022 | $38,534 | 19 | Regeneron Pharmaceuticals, Inc. ($9,014) |
| 2021 | $31,302 | 15 | Innate Pharma, Inc ($7,920) |
| 2020 | $16,249 | 9 | Regeneron Pharmaceuticals, Inc. ($7,533) |
| 2019 | $19,900 | 44 | E.R. Squibb & Sons, L.L.C. ($7,174) |
| 2018 | $24,519 | 38 | E.R. Squibb & Sons, L.L.C. ($10,978) |
| 2017 | $42,880 | 75 | E.R. Squibb & Sons, L.L.C. ($10,109) |
All Payment Transactions
235 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | BioNTech SE | — | — | Cash or cash equivalent | $2,740.00 | Research |
| Study: BNT111-01 | ||||||
| 12/05/2024 | Teva Pharmaceuticals USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,700.00 | General |
| 12/05/2024 | Teva Pharmaceuticals USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,700.00 | General |
| 09/06/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $4,085.00 | General |
| Category: ONCOLOGY | ||||||
| 09/06/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $1,634.00 | General |
| Category: ONCOLOGY | ||||||
| 09/06/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $1,225.50 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $112.79 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $64.41 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $17.69 | General |
| Category: ONCOLOGY | ||||||
| 07/10/2024 | BioNTech SE | — | — | Cash or cash equivalent | $2,055.00 | Research |
| Study: BNT111-01 | ||||||
| 05/10/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,081.50 | General |
| 02/01/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $922.50 | General |
| 01/03/2024 | PFIZER INC. | BRAFTOVI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,875.00 | General |
| Category: ONCOLOGY | ||||||
| 12/13/2023 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $1,230.00 | General |
| 11/30/2023 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $320.46 | Research |
| Study: REGN3767 CLINICAL DEVELOPMENT PROGRAM | ||||||
| 11/02/2023 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $351.32 | Research |
| Study: REGN3767 CLINICAL DEVELOPMENT PROGRAM | ||||||
| 11/01/2023 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $350.37 | Research |
| Study: REGN3767 CLINICAL DEVELOPMENT PROGRAM | ||||||
| 10/31/2023 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $122.80 | Research |
| Study: REGN3767 CLINICAL DEVELOPMENT PROGRAM | ||||||
| 10/19/2023 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $430.99 | Research |
| Study: REGN3767 CLINICAL DEVELOPMENT PROGRAM | ||||||
| 09/26/2023 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $122.80 | Research |
| Study: REGN3767 CLINICAL DEVELOPMENT PROGRAM | ||||||
| 09/08/2023 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,261.75 | General |
| 09/08/2023 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $122.80 | Research |
| Study: REGN3767 CLINICAL DEVELOPMENT PROGRAM | ||||||
| 09/08/2023 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $116.66 | Research |
| Study: REGN3767 CLINICAL DEVELOPMENT PROGRAM | ||||||
| 08/30/2023 | Sumitomo Pharma America, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,720.00 | General |
| 08/10/2023 | BioNTech SE | — | Consulting Fee | Cash or cash equivalent | $2,397.50 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| BNT111-01 | BioNTech SE | $4,795 | 2 |
| REGN3767 CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $2,621 | 11 |
| A PHASE II, RANDOMIZED STUDY OF ATEZOLIZUMAB ANTI-PD-L1 ANTIBODY ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA | F. Hoffmann-La Roche AG | $812.50 | 1 |
| A Phase II, Randomized Study of Atezolizumab Anti-PD-L1 Antibody Administered as Monotherapy or in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma | F. Hoffmann-La Roche AG | $756.70 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 195 | 471 | $151,485 | $32,662 |
| 2022 | 4 | 166 | 396 | $119,940 | $26,370 |
| 2021 | 6 | 189 | 401 | $126,455 | $28,182 |
| 2020 | 5 | 175 | 374 | $116,015 | $22,045 |
Total Patients
725
Total Services
1,642
Medicare Billing
$109,260
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 98 | 258 | $65,790 | $13,706 | 20.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 52 | 150 | $56,250 | $12,128 | 21.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 33 | 51 | $25,245 | $6,054 | 24.0% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 12 | 12 | $4,200 | $773.74 | 18.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 88 | 241 | $61,455 | $13,137 | 21.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 39 | 101 | $37,875 | $8,259 | 21.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 22 | 36 | $17,820 | $4,450 | 25.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 17 | 18 | $2,790 | $524.48 | 18.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 92 | 221 | $56,355 | $12,558 | 22.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 44 | 119 | $44,625 | $9,858 | 22.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 15 | 15 | $10,650 | $2,381 | 22.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 12 | 19 | $9,405 | $2,151 | 22.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 13 | 13 | $3,250 | $802.49 | 24.7% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 13 | 14 | $2,170 | $432.04 | 19.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 44 | 137 | $51,375 | $9,302 | 18.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 77 | 144 | $36,720 | $6,194 | 16.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 18 | 53 | $13,250 | $3,310 | 25.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 11 | 11 | $5,170 | $1,306 | 25.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 14 | 18 | $6,750 | $1,237 | 18.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 11 | 11 | $2,750 | $695.92 | 25.3% |
About Dr. Mario Sznol, MD
Dr. Mario Sznol, MD is a Medical Oncology healthcare provider based in North Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1073501748.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mario Sznol, MD has received a total of $222,168 in payments from pharmaceutical and medical device companies, with $27,213 received in 2024. These payments were reported across 235 transactions from 34 companies. The most common payment nature is "Consulting Fee" ($174,742).
As a Medicare-enrolled provider, Sznol has provided services to 725 Medicare beneficiaries, totaling 1,642 services with total Medicare billing of $109,260. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location North Miami, FL
- Active Since 10/07/2005
- Last Updated 01/15/2026
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1073501748
Products in Payments
- LIBTAYO (Biological) $9,832
- OPDIVO (Biological) $8,747
- Lumoxiti (Drug) $7,920
- BRAFTOVI (Drug) $7,500
- TECENTRIQ (Biological) $7,336
- Zelboraf (Biological) $5,609
- Copiktra (Drug) $5,146
- JZP-815 $3,600
- MEKINIST (Drug) $3,157
- Avastin (Biological) $2,948
- ADCETRIS (Biological) $2,468
- Non-Covered Product (Drug) $814.33
- APS001F (Drug) $800.00
- Defactinib (Drug) $764.75
- Tecentriq (Biological) $756.70
- LEUKINE (Drug) $700.00
- SANCUSO (Drug) $675.00
- MK-1308 (Drug) $487.50
- Proleukin (Drug) $348.61
- PROLEUKIN (Drug) $157.40
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.